News Release

July 24, 2023

Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Presentation of PPMX-T003 Phase I Interim Report at the 13th JSH International Symposium 2023

Perseus Proteomics Inc. is pleased to announce that the interim report presentation of phase I clinical trial of PPMX-T003, its anti-transferrin receptor antibody, among polycythemia vera ("PV") patients was made at the 13th JSH International Symposium 2023 in Tsukuba.

Date: July 21 – 22, 2023
Title: PHASE I SAFETY STUDY OF ANTI-TRANSFERRIN RECEPTOR ANTIBODY (PPMX-T003) IN PATIENTS WITH POLYCYTHEMIA VERA (INTERIM REPORT)
Author: Tomoki Ito/First Department of Internal Medicine, Kansai Medical University
Teruhito Takakuwa, Masayuki Hino, Hirohisa Nakamae/Department of Hematology, Osaka Metropolitan University
Keiko Katsumi, Tadashi Matsuura/Perseus Proteomics Inc.
Presenter: Teruhito Takakuwa

Dr. Takakuwa published the interim data details including the progress of the patients No. 1 through to No.3 during the entire observation period and presented that safety and dose-depending efficacy of limiting erythroblast of PPMX-T003 were confirmed.

END